[Corrigendum] GINS2 is a novel prognostic biomarker and promotes tumor progression in early‑stage cervical cancer.Subsequently to the publication of the above article, the authors have realized that Figs. 
GINS2
All the authors agree to the publication of this Corrigendum, and they thank the Editor of Oncology Reports for allowing them the opportunity to publish it.  [The original article was published in Oncology Reports 37: 2652‑2662, 2017; DOI: 10.3892/or.2017.5573].
Oncology Reports